Request a copy

Full Text

• Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
• Pietersma F.L., van Dorp S., Minnnema M.C., Kuball J., Meijer E., Schuurman R., et al. Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis 2011, 52:e144-e148.
• Özdemir E., Saliba R.M., Champlin R.E., Couriel D.R., Giralt S.A., de Lima M., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40:125-136.
• Zhou W., Longmate J., Lacey S.F., Palmer J.M., Gallez-Hawkins G., Thao L., et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113:6465-6476.
• Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 42:S70-S72.
• Boeckh M., Ljungman P. How we treat CMV in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
• Lurain N., Chou S. Antiviral drug resistance of cytomegalovirus. Clin Microbiol Rev 2010, 34:689-712.
• Ljungman P., Hakki M., Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011, 25:151-169.
• Shapira M.Y., Resnick I.B., Chou S., Neumann A.U., Lurain N.S., Stamminger T., et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008, 46:1455-1457.
• Schnepf N., Dhedin N., Mercier-Delarue S., Andreoli A., Mamez A.-C., Ferry C., et al. Dynamics of cytomegalovirus populations harboring mutations in genes UL54 and UL97 in a hematopoietic stem cell transplant recipient. J Clin Virol 2013, 58:733-736.
• Lilleri D., Gerna G., Zelinin P., Chiesa A., Rognoni V., Mastronuzzi A., et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PloS One 2012, 7:e41648.
• Schnepf N., Scieux C., Resche-Riggon M., Feghoul L., Xhaard A., Gallien S., et al. Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard. J Clin Microbiol 2013, 51:2096-2102.
• Hantz S., Garnier-Geoffroy F., Mazeron M.C., Garrigue I., Merville P., Mengelle C., et al. Drug resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010, 65:2628-2640.
• Muñoz-Cobo B., Solano C., Costa E., Bravo D., Clari M.A., Benet I., et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 2011, 17:1602-1611.
• Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190:177-182.
• van der Beek M.T., Marijt E.W., Vossen A., van der Blij-de Brouwer C.S., Wolterbeek R., Halkes C.J., et al. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients. Antiviral Ther 2012, 17:45-51.
• Buyck H.C.E., Griffiths P.D., Emery V.C. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. J Clin Virol 2010, 49:32-36.
• Junghanss C., Boeckh M., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002, 99:1978-1985.
• Nakamae H., Kirby K.A., Sandmaier B.M., Norasetthada L., Maloney D.G., Maris M.B., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:694-703.
• Xuan L., Huang F., Fan Z., Zhou H., Zhang X., Yu G., et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol 2012, 5:46.
• Miller W., Flynn P., McCullough J., Balfour H.H., Goldman A., Haake R., et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-versus-host disease. Blood 1986, 67:1162-1167.
• Moins-Teisserenc H., Busson M., Scieux C., Bajzik V., Cayuela J.-M., Clave E., et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2008, 198:818-826.
• Tormo N., Solano C., Benet I., Clari M.A., Nieto J., de la Cámara R., et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-specific IFN gamma CD8+ and CD4+ cells is associated with rising levels of pp65antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl 2010, 45:543-549.
• Allice T., Busca A., Locatelli F., Falda M., Pittaluga F., Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrobial Chemother 2009, 63:600-608.
• Shmueli E., Or R., Shapira M.Y., Resnick I.B., Caplan O., Bdolah-Abram T., et al. High rate of cytomegalovirus drug resistance in patients receiving antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014, 209:557-561.